Peter Hendricks Ph.D. – Is Psilocybin Helpful For People Who Abuse Cocaine?
Release Date: 06/30/2020
Psychedelics Today
In this episode, we sit down with ., to discuss why the future of psychedelic access in the United States is being shaped not by federal agencies, but by the bold actions of individual states. As a legal scholar and writer focusing on drug policy, Victoria breaks down the significance of the FDA’s 2024 rejection of psychedelic-assisted therapy, and why that decision might be less of a setback than it seems. We explore how state-level initiatives like Oregon’s Psilocybin Services Act and Colorado’s Natural Medicine Health Act are setting the stage for a new model of access—one rooted...
info_outlinePsychedelics Today
info_outlinePsychedelics Today
info_outlinePsychedelics Today
Joe Moore and Anne Philippi are hosts of the PS25 Morning Show! This one features Dee Dee Goldpaugh, LCSW and Tommaso Barba, PhDC! We talk about all things Sex and Psychedelics!
info_outlinePsychedelics Today
n this episode of Psychedelics Today, kicking of Psychedelic Science 2025 week in Denver, we sit down with Jonathan Dicksinson, Chief Executive Officer, and Trevor Millar, Chief Operations Officer of Ambio Life Sciences – one of the world’s leading ibogaine clinics – to explore the potential of ibogaine for addiction, neuroregeneration, and how ethics, honoring experience, and sustainability will be key to delivering ibogaine at scale. Trevor shares his early work supporting marginalized populations in Vancouver’s Downtown Eastside, which led to the founding of Liberty Root, one...
info_outlinePsychedelics Today
In this episode of Psychedelics Today, hosts sit down with Jeff Breau from Harvard Divinity School's Center for the Study of World Religions. Key themes include the intersection of psychedelics and religion, harm reduction practices, and the burgeoning psychedelic church movement. Jeff brings insights from his ethnographic research on psychedelic churches and discusses the importance of interdisciplinary collaboration for advancing understanding in this field. He also delves into the role of music in psychedelic therapy, critiques of the Mystical Experience Questionnaire (MEQ), and the...
info_outlinePsychedelics Today
In this episode, Joe Moore sits down with from to discuss a range of fascinating topics. They begin by discussing the Harvard Divinity School and the CSWR’s mission and history. The conversation delves into the work and legacy of , a pivotal figure in the 1960s psychedelic harm reduction movement. It explores her contributions to the field through her Psychedelic Information Center. They also touch on the Quaker traditions and their intersection with LSD use, showing how spirituality and psychedelics can coalesce. Paul also talks about upcoming psychedelic and chaplaincy workshops,...
info_outlinePsychedelics Today
In this episode of Psychedelics Today, Joe Moore speaks with Dr. Simon Ruffell, a London-based psychiatrist, researcher, and curandero-in-training in the López Mahua lineage of the Shipibo tradition. Dr. Ruffell shares how his early fascination with psychiatry eventually led to a deep disillusionment with the limitations of conventional treatments—and a surprising pivot toward the Amazon. Now working at the intersection of Indigenous healing and clinical research, Ruffell describes his journey from medical school to shamanic apprenticeship. He offers insight into the Shipibo understanding...
info_outlinePsychedelics Today
Aspen Psychedelic Symposium 2024 – Hosted by Kevin Franciotti This powerful panel explores the healing potential and complex responsibilities that come with working with Ibogaine, a potent plant-based psychedelic. Moderator Kevin Franciotti guides a heartfelt and informative conversation with Talia Eisenberg, Tom Feegel, and Dr. Lola "Dr. O" Hoba, highlighting personal transformation, medical protocols, and the importance of honoring traditional knowledge. Personal Journeys with Ibogaine Talia Eisenberg shares her recovery from opioid addiction and the founding of BEOND Ibogaine, a medical...
info_outlinePsychedelics Today
A panel discussion with Jim Harris, Rachel Zoeller, DPT, David W. McMillan, Ph.D., and Manesh Girn, Ph.D. Recorded live at the Aspen Psychedelic Symposium In this riveting and deeply personal conversation, moderator Jim Harris is joined by three pioneers at the intersection of neuroscience, psychedelics, and disability: Dr. Rachel Zoeller (Doctor of Physical Therapy and spinal cord injury survivor), Dr. David McMillan (Assistant Professor of Neurological Surgery at the University of Miami), and Dr. Manesh Girn (neuroscientist and postdoctoral researcher with Robin Carhart-Harris at UCSF)....
info_outlineIn this episode, Joe speaks with Peter Hendricks, Ph.D. and Associate Professor at the University of Alabama, currently involved in researching the effects of psilocybin on people dealing with cocaine-related substance use disorder.
He discusses the details of the pilot trial (following the Johns Hopkins model, with music created by Bill Richards), some early findings and speculations, what music might work best for these sessions, how excited he is to bring these findings to the criminal justice system, and how religion and tribalism come into play when looking at what people get out of these psychedelic experiences.
Hendricks points out that while psilocybin is currently being researched as a treatment for tobacco use (by Matthew Johnson at Johns Hopkins) and alcohol use (by Michael Bogenschutz at NYU), this is the first large study with cocaine and could lead to the first medication for major stimulants. And while there have been many studies on psilocybin in general, they’ve rarely been focused on the people he’s working with, who are often poorer, less educated, often out of work, and usually struggling more than those typically involved in these studies. They also talk about what research of the past has given us data-wise, and how inspirational it has been to the work being done today.
Notable Quotes
“The participants in our trial- they haven’t read Michael Pollan’s book or others. They’re not in the know. I’ll have to explain to them what the drug is, and the common reaction is, ‘uhh, so you’re going to help me stop getting high by getting me high?’ and I’ll try to explain how the drug might differ from others, from more addictive drugs like cocaine. And as we know, it’s an ineffable experience- it’s a difficult experience to put to words…. I’m honored and I have admiration for our participants because they have the courage to dive into this study conducted at a University by people they’ve never met. It can be a very frightening experience and they say, ‘you know what, I’ve tried everything. At this point, I’m desperate, let’s give it a try.’ I probably couldn’t overstate how much courage it takes for them to do what they do. I don’t know that I could do it myself.”
“I think for most of the world’s fates, the tenants are that we’re all in this together, and we’re bound by love. And that really might be the message that most people get from psychedelics, but similar to religion, sometimes that message is perverted a bit and what you take from it is, ‘my in-group is what’s most important and I’m going to act to preserve my own tribe, even if it means treating others in an awful, inhumane way…’ Sometimes experiences that are really meant to foster a connection with everybody can go haywire and we have to be aware of that”
“One criticism of some of the studies conducted so far has been, how do we know that psilocybin might have these effects on a sample that isn’t all college-educated or doctorates or who are Professors at Universities who make more than 100,000 dollars per year and live comfortably? How do we know that this experience would have any meaning to somebody who’s making less than 10,000 per year, who has a fifth-grade education, who’s unemployed and homeless? I think in large part, this study might answer that question. If we find an effect, then we can say it appears to also have an effect among those who look different and whose life circumstances are much different than some of the earlier participants.”
Links
Support the show
- Patreon
- Leave us a review on Facebook or iTunes
- Share us with your friends
- Join our Facebook group - Psychedelics Today group – Find the others and create community.
Navigating Psychedelics
About Peter Hendricks PhD
Dr. Hendricks received his doctorate in clinical psychology from the University of South Florida and completed a post-doctoral Fellowship in Drug Abuse Treatment and Services Research at the University of California, San Francisco. His research centers on the development of novel and potentially more effective treatments for substance dependence, with specific areas of focus on tobacco, cocaine, and polysubstance dependence in vulnerable populations.